

Abraham Morgentaler, MD, FACS

A. C. S.
8/25/15

Date Prepared: July 28, 2015
Office Address: 200 Boylston St., Chestnut Hill, MA 02467
Work Phone: 617-277-5000
Work Email: amorgent@bidmc.harvard.edu
Work FAX: 617-277-5444
Place of Birth: Montreal, Canada

Education

1978	Bachelor of Arts (magna cum laude)	Biology	Harvard College
1982	Doctor of Medicine	Medicine	Harvard Medical School

Postdoctoral Training

July/82- June/83	Intern	Surgery	New England Deaconess Hospital
July/83- June/84	Resident	Surgery	New England Deaconess Hospital
July/84- June/87	Resident	Urology	Harvard Program in Urology (Longwood Area)
July/87- June/88	Chief Resident	Urology	Harvard Program in Urology (Longwood Area)

Faculty Academic Appointments

July/82- June/88	Clinical Fellow	Department of Surgery	Harvard Medical School
Sept/88- Sept/93	Instructor	Department of Surgery (Urology)	Harvard Medical School
Sept/93- Sept/98	Assistant Professor	Department of Surgery (Urology)	Harvard Medical School
Aug/98- Aug/99	Associate Professor	Department of Surgery (Urology)	Harvard Medical School
Aug/99-	Associate Clinical Professor	Department of Surgery (Urology)	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

Sept/88-	Associate	Urology	Beth Israel Deaconess Medical Center
Jan/90- Jan/02	Surgeon		New England Surgicare
Feb/99-	Associate		Beth Israel Deaconess Cancer Center
Feb/02- Jan/02-	Courtesy Medical Staff Staff		Faulkner Hospital New England Baptist spital

Other Professional Positions

1994-2000	Staff Council	Beth Israel Deaconess Medical Center
1994-1995	Fixed Variable Cost Refinement Team	Beth Israel Deaconess Medical Center

Major Administrative Leadership Positions

Local

1988-1999	Director Men's Program for Sexual Dysfunction	Beth Israel Deaconess Medical Center
1988-1999	Director Male Fertility Program	Beth Israel Deaconess Medical Center
1990-1999	Director Andrology Laboratory	Beth Israel Deaconess Medical Center
1999-	Director Men's Health Boston	Brookline, Massachusetts

Committee Service

Local

1994-	Fiscal Reorganization Committee Department of Surgery	Beth Israel Deaconess Medical Center
1994-1995	Medical Staff Administration Committee	Beth Israel Deaconess Medical Center
1994-1995	Surgery Working Committee on Fiscal Recognition	Beth Israel Deaconess Medical Center
1995	Fixed and Variable Cost Committee	Beth Israel Deaconess Medical Center
1996-1998	Surgical Miniliason Committee	Beth Israel Deaconess Medical Center
1999-2004	Contract and Payment Committee	Beth Israel Deaconess Physicians Organization
2001-2002	Health Policy Committee	Sexual Society of North America

Professional Societies

1986	Massachusetts Medical Society	Member
1987-2002	American Medical Association	Member
1989-	American Urological Association	Member
1989-1993	American Society For Laser Medicine and Surgery	Member
1989-	American Society for Reproductive Medicine	Member

1989-	Society for the Study of Reproduction	Member
1989-	Massachusetts Association of Practicing Urologist	Member
1991-	American Society of Andrology	Member
1991-	International Society for Impotence Research	Member
1992-	Boston Fertility Society	Member
1992-	American College of Surgery	Member
1993-	American Association of Clinical Urologists	Member
1994-2001	Society for The Study of Impotence	Member
1994-	Society for the Study of Male Reproduction	Member
1999-2001	Society for Reproduction and Urology	Board Member
2001-	Sexual Medicine Society of North America	Member
2008-2010	Sexual Medicine Society of North America	Board of Directors

Editorial Activities

Journal of Fertility and Sterility
Journal of Plastics and Reconstructive Surgery
Journal of Urology
New England Journal of Medicine
Lancet
Journal of Andrology

Other Editorial Roles

1995-1997	Editorial Board	Physicians Home Page
1995-2006	Editorial Board	Journal of Long-Term Effects of Medical Implants
1996-	Guest Editor	Journal of Long-Term Effects of Medical Implants
1998-2001	Editorial Board	Journal of Andrology
2004-2007	Editorial Board	International Journal of Impotence Research
2006-	Editorial Board	Perspective in Prostate Disease
2007-2010	Editorial Board	Journal of Sexual Medicine

Honors and Prizes

1994-1996	New Investigator Research Award	American Foundation for Urologic Disease/Searle	Grant
2004	Excellence in Teaching	Harvard Medical School	Certificate of Recognition

Clinical Supervisory and Training Responsibilities

1990-1998	BIDMC Andrology Lab Laboratory Supervisor	250
-----------	--	-----

Report of Regional, National and International Invited Teaching and Presentations

Regional

1989-1995	Male Genital Examination, Introduction to Clinical Medicine, Lecture Harvard Medical School Boston
1989-1994	Male Genital Examination with Love Models, Introduction to Clinical Medicine, Lecture Harvard Medical School Boston
1990-	Harvard Science and Technology Course 070, Male Reproductive Anatomy and Physiology, Lecture Harvard Medical School Boston
1999-2004	Pathophysiology of Male Reproductive Disorders, Co-chair Harvard Medical School Boston
2003	Lessons from Viagra: The impact of sexual relations for men. Course: Understanding Boys and Men. Cambridge
2003	Testosterone and its relationship to men's health and illness. 1 st Massachusetts Medical Society Symposium on Men's Health Waltham
2004	Testosterone, the male climacteric, and relationships to prostate cancer. 2 nd Annual Massachusetts Medical Society Symposium on Men's Health Waltham
2004	Impact of urologic cancer surgery on sexuality. American College of Surgeons 32 nd Annual Spring Meeting Boston
2010	Love, Sex, and Intimacy: A Male Perspective. Course: Treating Couples Boston, MA

- 2011 Strange bedfellows: successful publishing via unusual alliances. CME course on Medical Publishing
Harvard Medical School
Boston
- 2012 Men's Health. Brigham and Women's Hospital's 33rd Annual Office Practice of Primary Care Medicine
Boston
- 2012 Update on Men's Health. Office Practice of Primary Care Medicine
Harvard Medical School
Boston
- 2012 Male Hypogonadism and the Role of Testosterone Replacement Therapy
PharmEd
Westborough, Massachusetts
- National**
- 1995- Frontiers in Molecular Biology, Lecture
Summer Research Conference, American Urologist
Houston, Texas
- 1998- Evaluation and Management of Male Fertility, Lecture
The American Urological Association
San Diego, California
- 1998 Postgraduate Course, Andrology, Lecture
American Society of Andrology
Long Beach, California
- 2002 Male Reproduction, Lecture
The Society for the Study of Male Reproduction
American Urologic Association
- 2004 Testosterone, Lecture
American Urological Association
- 2004 Male and Female Sexual Dysfunction, Lecture
The American Society for Reproductive Medicine
Philadelphia, Pennsylvania
- 2007 Importance of Hypogonadism and Testosterone Replacement Therapy in Current Urologic Practice, Lecture
American Urologic Association

- 2009 Treatment of Male testosterone deficiency during and after the reproductive years. Society of Male Reproduction/Urology, at the annual meeting of the American Society for Reproductive Medicine
Atlanta
- 2010 What are the major issues with testosterone replacement therapy? 20th
International Prostate Cancer Update
Vail
- 2011 Re-thinking old concepts: Testosterone therapy in men with prostate cancer.”
Paul C. Peters Urology Symposium, UT Southwestern Medical Center
Texas
- 2011 Testosterone deficiency: What the Urologist Needs to Know. Paul C. Peters
Urology Symposium, UT Southwestern Medical Center
Dallas
- 2011 What’s new with testosterone and prostate cancer? Sexual Medicine Society
symposium, Annual Meeting of the American Urological Association
Washington, DC
- 2011 Testosterone therapy and prostate cancer. Las Vegas Urological Society
Las Vegas
- 2011 Testosterone and prostate cancer: a revolution in medical thinking. Keynote
speaker, annual meeting of the Academy of Anti-Aging Medicine
Las Vegas
- 2012 New Concepts in Testosterone Therapy. Tampa Urological Society
Tampa
- 2012 What the Urologist Should Know About Testosterone Deficiency. Grand
Rounds, Henry Ford Hospital
Detroit
- 2012 Testosterone and Prostate Cancer: A Revolution in Thought.
Michigan Urological Society
Livonia
- 2012 Opioid-Induced Androgen Deficiency: Approaches to Diagnosis and
Management, American Academy of Pain Medicine
Palm Springs
- 2012 Prostate cancer and testosterone- the Changing Paradigm. Special
Symposium, American Society of Andrology
Tucson

- 2012 Interactive case studies. Testosterone Therapy and Prostate Health: Examining Barriers to Treatment of Hypogonadism, Dinner symposium, American Urological Association Annual meeting
Atlanta
- 2012 Testosterone deficiency and osteoporosis: What should the urologist know? Plenary lecture, American Urological Association Annual meeting
Atlanta
- 2009 Treatment of Male testosterone deficiency during and after the reproductive years. Society of Male Reproduction/Urology, at the annual meeting of the American Society for Reproductive Medicine
Atlanta
- International**
- 2008 Joint Congress of the European and International Societies for Sexual Medicine
Brussels, Belgium
- 2009 Rapidly changing perspectives regarding testosterone and prostate cancer Solvay Satellite Symposium, European Association of Urology
Stockholm, Sweden
- 2010 Testosterone and prostate cancer: Intriguing correlation? European Association of Urology
Barcelona, Spain
- 2011 Treatment and monitoring of TRT. British Association of Urological Surgeons
Liverpool, England
- 2011 TRT and prostate cancer: Is there an association? British Association of Urological Surgeons
Liverpool, England
- 2011 Testosterone therapy and prostate cancer, Colombian Society of Urologists
Bogota, Colombia
- 2011 Testosterone therapy and prostate cancer, Meeting of the Urological Association of Mexico
Mexico City, Mexico
- 2011 Adverse events associated with testosterone therapy: Criticism from the urologist. Annual Meeting of the European Society for Sexual Medicine
Milan, Italy

- | | |
|------|--|
| 2011 | Classic concepts: Is testosterone really dangerous for the prostate? Plenary session, Annual Meeting of the European Society for Sexual Medicine
Milan, Italy |
| 2012 | Testosterone and prostate cancer: new concepts. Congresso Americano Urologico
Cartagena, Colombia |
| 2012 | Testosterone treatment in men. World Organization of Anti-Aging Medicine
Sao Paulo, Brazil |
| 2012 | Testosterone and prostate cancer. World Organization of Anti-Aging Medicine
Sao Paulo, Brazil |

Current Licensure and Certification

- | | |
|------|--|
| 1983 | Diplomate, National Board of Medical Examiners |
| 1985 | Massachusetts Medical License |
| 1990 | Diplomate, American Board of Urology |
| 2007 | Recertified, American Board of Urology |

Recognition

- | | | |
|-----------|--------------------------------------|---|
| 1992-1993 | Who's Who in Science and Engineering | Marquis |
| 1994 | New Investigators Research Award | American Foundation for Urologic Disease/Searle |
| 1995 | Who's Who in America | Marquis |
| 2001-2002 | Best Doctor in America | Best Doctors |
| 2005 | Best Doctor in America | Best Doctors |

Peer reviewed publications in print or other media

Morgentaler A, Crews D: Role of the anterior hypothalamus-preoptic area in the regulation of reproductive behavior in the lizard, *Anolis carolinensis*: Implantation studies. *Hormones and Behavior*, 11:61, 1978

Crews D, Morgentaler A: Effects of intracranial implantation of oestradiol and dihydrotestosterone on the sexual behavior of the lizard *Anolis carolinensis*. *Journal of Endocrinology*, 82:373, 1979.

Morrell JJ, Crews D, Ballin A, Morgentaler A, Pfaff, DW: 3H-Oestradiol, 3H-Testosterone and 3H-Dihydrotestosterone localization in the brain of the lizard *Anolis carolinensis*: an autoradiograph study. *Journal of Comparative Neurology*, 188:201, 1979.

Morgentaler A, Schopperle WM, DeWolf WC: Protein expression in normal and infertile human spermatozoa. *Surgical Forum*, 37:632, 1986.

Morgentaler A, Garnick MB, Richie JP: Metastatic testicular teratoma invading the inferior vena cava. *Journal of Urology*, 140:149, 1988.

Belville JS, Morgentaler A, Loughlin KR, Tumeh SS: Spontaneous perinephric and subcapsular renal hemorrhage: evaluation with CT, US, and angiography. *Radiology*, 172:733, 1989.

Morgentaler A, Koufman CN: Treatment of an impacted fecalith with electrohydraulic lithotripsy. *New Engl J Med*, 322:855, 1990.

Morgentaler A, Belville JS, Tumeh SS, Richie JP, Loughlin KR: Spontaneous perirenal hemorrhage: Rational approach to evaluation and management. *Surgery, Gynecology, and Obstetrics*, 170:121, 1990.

Morgentaler A, Bridge S, Dretler SP: Management of the impacted ureteral calculus. *Journal of Urology*, 143:263, 1990.

Morgentaler, A, Crocker RH, Schopperle WM, DeWolf WC: Protein differences between normal and oligospermic human sperm demonstrated by two-dimensional gel electrophoresis. *Fertility and Sterility*, 54:902, 1990.

Morgentaler A: Current diagnosis and management of impotence. *Comprehensive Therapy*, 17(7):25, 1991

Green LS, Schopperle WM, DeWolf WC, Morgentaler A: Temperature dependent expression of a 95 kD protein in rat testis. *Surg Forum*, 42:619, 1991.

Ho GT, Gardner H, DeWolf WC, Loughlin KR, Morgentaler A: Influence of testicular carcinoma on ipsilateral spermatogenesis. *J Urol*, 148:821, 1992.

Kritsas JJ, Schopperle WM, DeWolf WC, Morgentaler A: Rapid high-resolution two-dimensional electrophoresis of human sperm proteins. *Electrophoresis*, 13:445, 1992.

Morgentaler A, DeWolf WC: A self-expanding prostate stent for bladder outlet obstruction in high risk patients. *J Urol*, 150: 1636, 1993.

Morgentaler A, DeWolf WC. Re: Vasectomy and increased risk of prostate cancer. *JAMA*, 270:705, 1993

Ho GT, Gardner H, Mostofi K, DeWolf WC, Loughlin KR, Morgentaler A: Effect of testicular nongerm cell tumors on local spermatogenesis. *Fertility and Sterility*. 62:162, 1994.

Morgentaler A. Re: Hyponatremic encephalopathy after endometrial ablation. *JAMA*, 271: 344, 1994.

Bruning, CO III, Morgentaler A. Re: Unilateral unitary inflatable penile prosthesis to correct impaired tumescence and severe penile deformity resulting from traumatic rupture of 1 corpus cavernosum. *J Urol*, 154:1144, 1995.

Watson DL, Morgentaler A. Re: Spontaneous corporeal herniation of penis: new abnormality of tunica albuginea. J Urol 154:1144, 1995.

Watson DL, Morgentaler A: Spontaneous corporal herniation of the penis: A new abnormality of the tunica albuginea? J Urol, 153:737-40, 1995.

Rubenstein SC, Green LS, Schopperle WM, DeWolf WC, Morgentaler A: Temperature-dependent expression of a 95 KD protein in rat testis. Andrologia 27:107-113, 1995.

Brown LF, Yeo K-T, Berse B, Morgentaler A, Dvorak HF, Rosen S: Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 154:576-9, 1995.

Bruning CO, III, Breslin DS, Morgentaler A, Staskin DR: Experience with the penile prosthesis and artificial urinary sphincter. J of Long-Term Effects of Medical Implants 5:27-45, 1995.

Morgentaler A, Fung MY, Harris DH, Powers RD, Alper MM: Sperm morphology and IVF outcome: a direct comparison of World Health Organization and strict criteria methodologies. Fertility & Sterility 64:1177-82, 1995.

Comiter CV, Bruning CO, III, Morgentaler A: Detached ciliary tufts in the epididymis: a lesson in applied anatomy. Urology 46:740-2, 1995.

Maranchie J, Morgentaler A: Management of impending sterility. Lancet, p1344, May 11, 1996.

Dahl DM, Klein D, Morgentaler A: Penile mass caused by the newly described organism Mycobacterium celatum. Urology 47:266-8, 1996.

Socher S, Morgentaler A, DeWolf WC: Ureteral pseudodiverticulosis: the case for the retrograde pyelogram. Urology 47:924-7, 1996.

Morgentaler A, Bruning CO, III, DeWolf WC: Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 276:1904-6, 1996.

Vrachliotis TG, Rosen MP, Morgentaler A, Kim D: Aberrant supply of the common penile artery from an inferior epigastric/external pudendal artery trunk: radiological and urological implications. Vascular Surgery 31:495-9, 1997.

Vohra S, Morgentaler A: Congenital anomalies of the vas deferens, epididymis, and seminal vesicles. Urology 49:313-21, 1997.

Khoudary K, Morgentaler A: Design considerations in penile prostheses: the American Medical Systems product line. Journal of Long-Term Effects of Medical Implants 7:55-64, 1997.

Morgentaler A: Editorial. J Long-Term Effects of Medical Implants. 7:iv, 1997.

Yin Y, Hawkins KL, DeWolf WC, Morgentaler A: Heat stress causes testicular germ cell apoptosis in adult mice. J Andrology 18:159-65, 1997.

Socher SA, Yin Y, DeWolf WC, Morgentaler A: Temperature-mediated germ cell loss in the testis is associated with altered expression of the cell-cycle regulator p53. *J Urol* 157:1986-9, 1997.

Khoudary K, DeWolf WC, Bruning CO, III, Morgentaler A: Immediate sexual rehabilitation in radical prostatectomy patients by simultaneous placement of penile prosthesis: initial results in 50 patients. *Urology* 50:395-9, 1997.

Yin Y, DeWolf WC, Morgentaler A: p53 is associated with the nuclear envelope in mouse testis. *Biochemical and Biophysical Research Communications* 235: 689-94, 1997.

Morgentaler A: Causality and association- more than just different shades of gray. *Fertil Steril* 68:745, 1997.

Morgentaler A: Motile organisms in the epididymis? *Hum Reprod* 13:2335, 1998.

Khoudary K, Morgentaler A: Partial duplication of the vas deferens. *Journal of Urol* 159:988-9, 1998.

Yin Y, DeWolf WC, Morgentaler A: Experimental cryptorchidism induces testicular germ cell apoptosis by p53-dependent and -independent pathways. *Biology of Reproduction* 58:492-496, 1998.

Yin Y, Stahl B, DeWolf W, Morgentaler A: p53-Mediated germ cell quality control in spermatogenesis. *Dev Biol* 204:165-171, 1998.

Yin Y, Stahl BC, DeWolf WC, Morgentaler A: Heat-induced testicular apoptosis occurs independently of hormonal depletion. *Apoptosis* 1998; 3: 281-287.

Morgentaler A: Office evaluation in male sexual dysfunction. *International Journal Proctological and Perineal Diseases* II;2-3:362-363, 1998.

Morgentaler A: Motile organisms in the epididymis? *Hum Reprod* 13:2335, 1998.

Morgentaler A, Stahl B, Yin Y: Testis and temperature: An historical, clinical, and research perspective. *Journal of Andrology* 20:189-195, 1999.

Morgentaler A: Male Impotence. *Lancet* 354:1713-18, 1999.

Hoffman M, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? *Journal Urol* 163:824-827, 2000.

Schwartz C, Covino N, Morgentaler A, DeWolf WC: Quality-of-life after penile prosthesis placed at radical prostatectomy. *Psychology and Health* 15:651-661, 2000.

Zhang, Ping L, Bubley G, Upton M, Morgentaler A, DeWolf WC, Rosen S: Pathological features of occult prostatic carcinoma in hypogonadal men. *The Prostate Journal* 2:74-79, 2000.

Levine L, Estrada C, Morgentaler A: Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: Results of a 2 Center Study. *Journal of Urology* 166:932-937, 2001.

Yin Y, Stahl B, DeWolf WC, Morgentaler A: p53 and Fas Are Sequential Mechanisms of Testicular Germ Cell Apoptosis. *Journal of Andrology* 23:64-70, 2002.

Rhoden EL, Morgentaler A: Erectile Dysfunction. *Journal Long-Term Effects Med Implants* 13:519-28, 2003

Rhoden EL, Gobbi D, Rhoden CR, Menti E, Roehe AN, Hartmann A, Morgentaler A. Effects of chronic administration of dehydroepiandrosterone on serum testosterone levels and prostatic tissue in rats. *Journal Urol* 170:2101-3, 2003.

Rhoden EL, Morgentaler A: Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. *Journal Int Impot Res* 16:95-7, 2004.

Morgentaler A. Testosterone replacement therapy: benefits, risks, and controversies. *Curr Sexual Health Reports* 1:67-71, 2004.

Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. *New England Journal Med* 350:482-92, 2004.

Morgentaler A. Clinical Crossroads: A 66-year-old man with sexual dysfunction. *JAMA* 291:2994-3003, 2004.

Guay AT, Harman SM, Morgentaler A. Controversies in testosterone replacement therapy. *Patient Care* 38:19-25, 2004.

Cady B, Miner T, Morgentaler A. Part 2: Surgical Palliation of advanced illness: What's new, what's helpful. *Journal Am Coll Surg* 200:281-90, 2005.

Cady B, Barker F, Easson A, Aboulafia AJ, Ferson PF, Miner T, Morgentaler A. Part 3: Surgical Palliation of advanced illness: What's new, what's helpful. *Journal Am Coll Surg* 200:457-66, 2005.

Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy *Journal Urol.* 174:1395-8, 2005.

Morgentaler A. Androgen therapy and prostate disease. *Uro-news. Sonderheft* 1, 2005.

Morgentaler A. Androgen therapy and prostate disease. Report of the committee on androgen replacement therapy in men at risk for prostate disease. *Proceedings of the 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases.* Paris, 2005.

Lazarou S, Morgentaler A. Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. *Curr Urology Reports* 6:476-81, 2005.

Morgentaler A, Wu A, Kaplan I. Testosterone replacement therapy and prostate safety: an overview of the issues. *Geriatrics and Aging* 8: S4-7, 2005.

- Morgentaler A. Testosterone and the prostate: is there really a problem? *Contemporary Urology* 18:26-33, 2006.
- Morgentaler A, Rhoden EL. Re: prostate cancer in men using testosterone supplementation *J Urol* 175:1572, 2006.
- Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. *Int J Impot Res* 18:201-5, 2006.
- Morgentaler A . Testosterone replacement therapy and prostate risks: where's the beef? *Can J Urol*. 13:S40-3, 2006
- Morgentaler A Barada J, Niederberger C, Donatucci C, Garcia CS, Natanegara F, Ahuja S, Wong DG. Efficacy and Safety of Tadalafil Across Ethnic Groups and Various Risk Factors in Men with Erectile Dysfunction: Use of A Novel Non-Inferiority Study Design. *J Sexual Med* 3:492-503, 2006.
- Lazarou S, Reyes-Vallejo L, Morgentaler A. Phleboliths in varicoceles presenting as spermatic cord mass. *Fertility and Sterility*, 86: 219. 2006.
- Lazarou S, Reyes-Vallejo L, Morgentaler A. Wide Variability in Laboratory Reference Values for Serum Testosterone. *J Sexual Med*, 3:1085-9, 2006.
- Morgentaler A. Testosterone therapy for men at risk for or with history of prostate cancer. *Curr Treatment Options in Oncology*, 7: 363-9, 2006.
- Morgentaler A. Hypogonadism: Causes, Cures, and Concerns—A Pharmacist's Perspective. *University of Tennessee Advanced Studies in Pharmacy*, 3:136-41, 2006.
- Lazarou S, Reyes-Vallejo L, Morgentaler A. Technical advances in penile prostheses. *J Long Term Eff Med Implants*, 16:235-47, 2006.
- Reyes-Vallejo L, Lazarou S, Morgentaler A. Y chromosome microdeletions and male infertility: who should be tested and why? *BJU Int*, 97:441-3, 2006.
- Morgentaler A. Testosterone and Prostate Cancer: An historical perspective on a modern myth. *Eur Urology*, 50:935-9, 2006.
- Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. *Urology* 68:1263-7, 2006.
- Morgentaler A. Testosterone and sexual function. *Med Clinics of North America*. 90:S32-4, 2006.
- Morgentaler A. Commentary: Guideline for male testosterone therapy: a clinician's perspective. *J Clin Endocrinol Metab*. 2007; 92:416-7.
- Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. The association of time of day and serum

testosterone concentration in a large screening population. *BJU Int.* 2007; 100:509-13.

Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. *Journal Sex Med.* 2007; 4:538-43.

Morgentaler A. Cultural biases and scientific squabbles: the challenges to acceptance of testosterone therapy as a mainstream medical treatment. *Aging Male.* 2007; 10:1-2.

Reyes-Vallejo L, Lazarou S, Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone. *Journal Sexual Med* 4:1757-62, 2007.

Lux M, Reyes-Vallejo L, Morgentaler A, Levine LA. Outcomes and satisfaction rates for the redesigned 2-piece penile prosthesis. *Journal Urol* 177:262-6, 2007.

Loughlin KR, Morgentaler A, Sanda M, Garnick MB. Harvard experts discuss benign prostatic hyperplasia drug treatments. *Perspect Prost Disease* 1:37-47, 2007.

Morgentaler A. New concepts regarding the relationship of testosterone and prostate cancer. *Future Oncology* 3:123-6, 2007.

Rosen RC, Carson CC, Guay A, Keane T, McCullough A, Miner M, Morgentaler A, Notman DD, Shabsigh R, Spark RF, Optimizing testosterone replacement therapy in hypogonadal men. *Contemporary Urology* 19:30-36, 2007

Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. *European Urology* 52:623-5, 2007.

Morgentaler A. Testosterone replacement therapy and prostate cancer. *Urol Clin NA* 34:555-63, 2007.

Morgentaler A. Words of wisdom: re: Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. *European Urology* 53: 1084-88, 2008.

Lazarou S, Morgentaler A. The effect of aging on spermatogenesis and pregnancy outcomes. *Urol Clin NA* 35: 331-9, 2008.

Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Swerdloff RS, Wang C. Long-Acting Testosterone Undecanoate Therapy for Men With Hypogonadism: Results of a Pharmacokinetic Clinical Study. *J Urol*, 180:2307-13, 2008.

Morgentaler A, Traish A. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. *Eur Urol* 55:310-20. 2009.

Rhoden EL, Riedner CE, Morgentaler A. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. *J Urol* 179:1741-4, 2008.

Dobs AS, Morgentaler A. Does testosterone therapy increase the risk of prostate cancer? *Endocr Pract*

14:904-11, 2008.

Morgentaler A. Guilt by association A Historical Perspective on Huggins, Testosterone Therapy, and Prostate Cancer. *J Sex Med.* 2008;5:1834-40.

Morgentaler A, Schulman C. Testosterone and prostate safety. *Front Horm Res* 37:197-203, 2009.

Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. *J Urol* 181:972-9, 2009.

Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. *J Sex Med* 6:574-7, 2009.

Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. Testosterone and prostate cancer: revisiting old paradigms. *Eur Urol* 56(1):48-56, 2009.

Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. *J Sex Med* 6(6):1729-35, 2009.

Morgentaler A. Rapidly shifting concepts regarding androgens and prostate cancer. *ScientificWorldJournal* 9:685-90, 2009.

Morgentaler A. Point: Testosterone therapy in older men: the next big thing in medicine? *Clinical Geriatrics* 17:22-24, 2009.

Moreno SA, Shyam A, Morgentaer A. Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population. *J Sex Med* 7:1948-53, 2010.

Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, Morgentaler A, Miner MM. Assessing symptoms of hypogonadism by self-administered questionnaire: qualitative finding in patients and controls. *Aging Male* 12:77-85, 2009.

Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. *Br J Cancer* 101:1949-1956, 2009.

Miner MM, Sigman M, Morgentaler A. Erectile dysfunction as a marker for cardiovascular disease. *Sexuality, Reproduction, and Menopause*, 2009;7:27-32.

Heldwein FL, Rhoden EL, Morgentaler A. Classics of urology: a half century history of the most frequently cited articles (1955-2009). *Urology* 75:1261-8, 2010.

Rhoden EL, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. *J Sex Med* 7:277-83, 2010.

Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Endocrine aspects of male sexual dysfunctions. *J Sex Med* 7:1627-56, 2010.

Glina S, Rivero MA, Morales A, Morgentaler A. Studies on prostatic cancer I. The effect of castration, of

estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. J Sex Med 7:640-4, 2010.

Morgentaler A, Morales A. Should hypogonadal men with prostate cancer receive testosterone? J Urol 184:1257-60, 2010.

Morgentaler A, Rhoden EL, Guay A, Traish A. Re: Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int 105(6):884-5, 2010.

Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, Miner MM, Shabsigh R. The NERI Hypogonadism Screener: Psychometric Validation in Male Patients and controls. Clin Endocrinol (OXF), 74:248-56, 2011.

Morgentaler A. Words of wisdom. Re: Adverse events associated with testosterone administration. Eur Urol 59: 465, 2011.

Morgentaler A, Lipshultz LI, Avila D, Jr, Bennett R, Sweeney M, Khera M. Testosterone Therapy in Men With Untreated Prostate Cancer. J Urol 185:1256-61, 2011

Morgentaler A. Turning Conventional Wisdom Upside-Down: Low Serum Testosterone and High-Risk Prostate Cancer. Cancer, 117:3885-8, 2011.

Traish AM, Miner M, Zitzmann M, Morgentaler A. Testosterone deficiency. Am J Medicine, 124, 578-587, 2011.

Morgentaler A. Testosterone and Prostate Cancer: What Are the Risks for Middle Aged Men? Urol Clin NA, 2011;38:119-24.

Jannini EA, Gravina GL, Morgentaler A, Morales A, Incrocci L, Hellstrom WJ. Is testosterone a friend or a foe of the prostate? J Sex Med. 8:946-55, 2011.

McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A Multi-Institutional Observational Study of Testosterone Levels after Testosterone Pellet (Testopel®) Insertion. J Sex Med. J Sex Med. 9:594-601, 2012.

Di Sante S, Connors WP, Morgentaler A. Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy. J Sex Med 9:585-93, 2012

Connors W, Flinn K, Morgentaler A. Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy. J Sex Med. 8:3465-70, 2011

Kacker R, Traish AM, Morgentaler A. Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency. J Sex Med 9:1681-96, 2012

Morgentaler A. Goodbye androgen hypothesis, hello saturation model. Eur Urol 62:765-7, 2012

Morgentaler A. Low testosterone levels are related to poor prognosis factors in men with prostate cancer

prior to treatment. BJU Int. epub May 15, 2012

Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 189:S26-33, 2013

Linares Espinos E, Martinez-Salamanca JL, Morgentaler A, Moncada L, del Portillo L, Rodriguez-Izquierdo M, areche J, Carballido J. Patient with testosterone deficit syndrome after radical prostatectomy. Arch Esp Urol. 66(7):663-8, 2013

Kacker R, Connors W, Zade J, Morgentaler A. Bone mineral density and response to treatment in men less than fifty years with testosterone deficiency and sexual dysfunction or infertility. J Urol. S0022-5347(13)05687-5, 2013

Traish AM, Morgentaler A. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5 α -reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 138:462, 2013

Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia, 2013

Connors W, Morgentaler A. The evaluation and management of testosterone deficiency: the new frontier in urology and men's health. Curr Urol Rep. 14(6):557-64, 2013

Kacker R, Hornstein A, Morgentaler A. Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population. Aging Male 16(4):164-8, 2013

Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. 65(1):115-23, 2014

Kacker R, Harisaran V, Given L, Miner M, Rittmaster R, Morgentaler A. Dutasteride in men receiving testosterone therapy: a randomized, double-blind study. Andrologia. 2014

Morgentaler A, Traish AM, Kacker R. Deaths and cardiovascular events in men receiving testosterone. JAMA 5;311(9):961-2, 2014

Morgentaler A, Kacker R. Andrology: Testosterone and cardiovascular risk-deciphering the statistics. Nat Rev Urol. 11(3):131-2, 2014

Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! J Sex Med. 11(3):624-9, 2014

Professional educational materials or reports, in print or other media

Morgentaler A, and Tobin M: Prostatic Stents. Medical Outlook for Urologists, Cortlandt

Morgentaler A: The Male Body: A Physician's Guide to What Every Man Should Know About His Sexual Health. New York, Simon and Schuster, 1993.
Communications, Vol. 7, no. 2, 1993.

Morgentaler A, and Khoudary K: Occult prostate cancer in men with low serum testosterone. Medical Outlook for Urologists, Cortland Communications, Vol. 11, no. 1, 1997.

Morgentaler A: The Viagra Myth: The Surprising Impact on Love and Relationships. San Francisco, Jossey-Bass/Wiley, 2003.

Morgentaler A. Indicators and risks of testosterone replacement therapy and recommendations for monitoring. Audio-Digest Urology 29:01, January 2006.

Morgentaler A: Testosterone For Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall Health. Boston, McGraw-Hill, 2009.

Narrative Report (limit to 500 words)

•
The course of my 25 years in urological practice has been almost exclusively devoted to men's health issues- male sexual dysfunction, infertility, and testosterone deficiency. I was one of the earliest clinical investigators in the modern era of testosterone deficiency and its treatment. Together with several colleagues, my work has resulted in radical changes in concepts regarding testosterone (T) and prostate cancer (PCa). We have shown that low T is not protective against PCa, high T does not appear to contribute to PCa, and that T therapy may be offered to selected men with PCa without apparent increased risk of cancer recurrence. This work has led to numerous speaking invitations in the US and internationally.

My first 11 years following graduation from urological residency were spent as fulltime faculty at Beth Israel Deaconess Medical Center (formerly Beth Israel Hospital), where my clinical duties included developing the Men's Program for Sexual Dysfunction. I also created and served as medical director of the Andrology Laboratory, which performed male fertility tests such as semen analysis. During these years I was awarded the New Investigator award from the American Foundation for Urological Disease, which included two years of research funding. My laboratory investigated the biochemical mechanisms by which core body temperature impaired spermatogenesis, leading to several publications. In 1999 I opened the first Men's health center in the US, called Men's Health Boston, and became part-time faculty at BIDMC.

Publications of note included: demonstration that men with low serum T and normal PSA have a significant risk of PCa (JAMA 1996); serum T was inversely related to prostate cancer risk in T-deficient men (Urology 2006); first literature review concluding that there was no evidence supporting the longstanding belief that high serum T contributed to PCa (NEJM 2004); rates of subjective response to T therapy stratified by baseline T (J Sex Med 2007); first evidence linking T deficiency to Peyronie's

disease (J Sex Med 2009); providing a new (and now widely accepted) theoretical construct for understanding the relationship of T and PCa (the Saturation Model, Eur Urol 2009); reporting first experience with T therapy in men with untreated PCa (J Urol 2011).

Teaching highlights include training medical students and residents in office and operating room andrology, training four international research fellows and three clinical fellows, and teaching male anatomy and physiology for twenty years in the Harvard Medical School/HST course on Human Reproduction. I also taught for several years in an HMS pathophysiology course, for which I was given an award for Excellence in Teaching in 2004. I have also taught in multiple postgraduate medical programs, including invited lectures in over a dozen countries. Together with Dr. DeWolf, I am co-director of the HMS Continuing Education course on Men's Health. I have been co-chair of the popular Endocrine Forum at the AUA for the last ten years, and have participated in several plenary programs at that same meeting.

In summary, my career has been devoted to investigation, teaching, and excellence in clinical service.